BR112014010617A2 - derivados de 2-(1,2,3-triazol-2-il)benzamida e 3-(1,2,3-triazol-2-il)picolinamida como antagonistas do receptor de orexina - Google Patents

derivados de 2-(1,2,3-triazol-2-il)benzamida e 3-(1,2,3-triazol-2-il)picolinamida como antagonistas do receptor de orexina

Info

Publication number
BR112014010617A2
BR112014010617A2 BR112014010617A BR112014010617A BR112014010617A2 BR 112014010617 A2 BR112014010617 A2 BR 112014010617A2 BR 112014010617 A BR112014010617 A BR 112014010617A BR 112014010617 A BR112014010617 A BR 112014010617A BR 112014010617 A2 BR112014010617 A2 BR 112014010617A2
Authority
BR
Brazil
Prior art keywords
triazol
benzamide
orexin receptor
receptor antagonists
picolinamide
Prior art date
Application number
BR112014010617A
Other languages
English (en)
Other versions
BR112014010617A8 (pt
BR112014010617B1 (pt
Inventor
Heidmann Bibia
Brotschi Christine
Boss Christoph
T Williams Jodi
Bolli Martin
Sifferlen Thierry
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of BR112014010617A2 publication Critical patent/BR112014010617A2/pt
Publication of BR112014010617A8 publication Critical patent/BR112014010617A8/pt
Publication of BR112014010617B1 publication Critical patent/BR112014010617B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

resumo derivados de 2-(1,2,3-triazol-2-il)benzamida e 3-(1,2,3-triazol-2-il)picolinamida como antagonistas do receptor de orexina a presente invenção refere-se aos derivados de 2-(1,2,3-triazol-2-il)benzamida e 3-(1,2,3-triazol-2-il)picolinamida da fórmula (i) fórmula (i) em que ar1, q, e r1 até r5 são tais como expostos na descrição, à sua preparação, aos seus sais farmaceuticamente aceitáveis, e ao seu uso como produtos farmacêuticos, às composições farmacêuticas que contêm um ou mais compostos da fórmula (i), e especialmente ao seu uso como antagonistas do receptor de orexina. 157 1/1
BR112014010617-7A 2011-11-08 2012-11-07 Derivados de 2-(1,2,3-triazol-2-il)benzamida e 3-(1,2,3-triazol-2-il)picolinamida como antagonistas do receptor de orexina BR112014010617B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IBPCT/IB2011/054976 2011-11-08
IB2011054976 2011-11-08
PCT/IB2012/056218 WO2013068935A1 (en) 2011-11-08 2012-11-07 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives as orexin receptor antagonists

Publications (3)

Publication Number Publication Date
BR112014010617A2 true BR112014010617A2 (pt) 2017-04-25
BR112014010617A8 BR112014010617A8 (pt) 2017-12-26
BR112014010617B1 BR112014010617B1 (pt) 2021-12-14

Family

ID=47258050

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014010617-7A BR112014010617B1 (pt) 2011-11-08 2012-11-07 Derivados de 2-(1,2,3-triazol-2-il)benzamida e 3-(1,2,3-triazol-2-il)picolinamida como antagonistas do receptor de orexina

Country Status (28)

Country Link
US (1) US9150566B2 (pt)
EP (1) EP2776430B1 (pt)
JP (1) JP5718535B2 (pt)
KR (1) KR101676930B1 (pt)
CN (1) CN103917538B (pt)
AR (1) AR088692A1 (pt)
AU (1) AU2012335194B2 (pt)
BR (1) BR112014010617B1 (pt)
CA (1) CA2846568C (pt)
CL (1) CL2014000659A1 (pt)
CY (1) CY1117638T1 (pt)
DK (1) DK2776430T3 (pt)
EA (1) EA024106B1 (pt)
ES (1) ES2572703T3 (pt)
HK (1) HK1199022A1 (pt)
HR (1) HRP20160678T1 (pt)
HU (1) HUE029239T2 (pt)
IL (1) IL232462A (pt)
IN (1) IN2014CN04127A (pt)
MX (1) MX343837B (pt)
MY (1) MY167791A (pt)
PL (1) PL2776430T3 (pt)
SG (1) SG11201401665WA (pt)
SI (1) SI2776430T1 (pt)
TW (2) TWI555747B (pt)
UA (1) UA112317C2 (pt)
WO (1) WO2013068935A1 (pt)
ZA (1) ZA201404189B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
NZ628491A (en) 2012-02-07 2016-06-24 Eolas Therapeutics Inc Substituted prolines / piperidines as orexin receptor antagonists
CN104334544B (zh) 2012-06-04 2016-10-19 埃科特莱茵药品有限公司 苯并咪唑脯氨酸衍生物
CA2902135A1 (en) 2013-03-12 2014-09-18 Actelion Pharmaceuticals Ltd Azetidine amide derivatives as orexin receptor antagonists
TWI664177B (zh) 2013-12-03 2019-07-01 瑞士商愛杜西亞製藥有限公司 晶形
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
UA116053C2 (uk) 2013-12-04 2018-01-25 Ідорсія Фармасьютікалз Лтд Застосування похідних бензоімідазолу-проліну
CN105814042B (zh) * 2013-12-13 2018-09-28 大正制药株式会社 噁嗪烷化合物的晶形及其制造方法
JP2017024990A (ja) * 2013-12-13 2017-02-02 大正製薬株式会社 オキサゾリジン及びオキサジナン誘導体
EP3143999A4 (en) 2014-05-16 2017-12-20 The University of Tokyo Depression treatment agent
ES2901418T3 (es) 2014-08-13 2022-03-22 Eolas Therapeutics Inc Difluoropirrolidinas como moduladores del receptor de orexina
WO2016095205A1 (en) * 2014-12-19 2016-06-23 Merck Sharp & Dohme Corp. Heteroaryl orexin receptor antagonists
CN104557744B (zh) * 2014-12-23 2017-04-12 广东东阳光药业有限公司 一种三氮唑化合物的制备方法
US10370380B2 (en) 2015-11-23 2019-08-06 Sunshine Lake Pharma Co., Ltd. Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof
PT3414241T (pt) 2016-02-12 2022-07-29 Astrazeneca Ab Piperidinas substituídas por halo como moduladores de recetores de oxerina
TWI756418B (zh) 2017-05-03 2022-03-01 瑞士商愛杜西亞製藥有限公司 2-([1,2,3]三唑-2-基)-苯甲酸衍生物之製備
WO2020099511A1 (en) * 2018-11-14 2020-05-22 Idorsia Pharmaceuticals Ltd Benzimidazole-2-methyl-morpholine derivatives
GB201901142D0 (en) * 2019-01-28 2019-03-20 Heptares Therapeutics Ltd OX1 Antagonists
TW202241447A (zh) 2021-02-02 2022-11-01 瑞士商愛杜西亞製藥有限公司 (4-甲基-2-[1,2,3]三唑-2-基-苯基)-[(r)-3-(3-[1,2,3]三唑-2-基-苄基)-嗎啉-4-基]-甲酮之結晶形式
TW202400149A (zh) * 2022-05-13 2024-01-01 瑞士商愛杜西亞製藥有限公司 經噻唑并芳基-甲基取代之環狀肼-n-甲醯胺衍生物
CN115947697A (zh) * 2022-12-28 2023-04-11 苏州汉德创宏生化科技有限公司 一种3-氧代吗啉-4-羧酸叔丁酯的合成方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130432A (en) 1990-12-21 1992-07-14 Syntex (U.S.A.) Inc. Process for preparing cyclic amines and intermediate products thereof
AU676993B2 (en) 1991-06-27 1997-04-10 Virginia Commonwealth University Sigma receptor ligands and the use thereof
EP1435955A2 (en) * 2001-05-05 2004-07-14 SmithKline Beecham P.L.C. N-aroyl cyclic amine derivatives as orexin receptor antagonists
GB0115862D0 (en) * 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
ES2266549T3 (es) * 2001-06-28 2007-03-01 Smithkline Beecham Plc Derivados de n-aroil-amina ciclicos como antagonistas del receptor de orexina.
GB0124463D0 (en) * 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
GB0130335D0 (en) * 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
NZ550216A (en) 2004-03-01 2009-08-28 Actelion Pharmaceuticals Ltd Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
EA015256B1 (ru) 2006-03-15 2011-06-30 Актелион Фармасьютикалз Лтд. Производные тетрагидроизохинолина для повышения функции памяти
JP2009543785A (ja) 2006-07-14 2009-12-10 メルク エンド カムパニー インコーポレーテッド 架橋ジアゼパンオレキシン受容体アンタゴニスト
GB0620818D0 (en) 2006-10-19 2006-11-29 Ucb Sa Therapeutic agents
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
EP2207778A2 (en) 2007-09-24 2010-07-21 Actelion Pharmaceuticals Ltd. Pyrrolidines and piperidines as orexin receptor antagonists
PE20091010A1 (es) 2007-10-10 2009-08-08 Actelion Pharmaceuticals Ltd Derivados de tetrahidroquinolina
WO2010048013A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted morpholine orexin receptor antagonists
JP2012506375A (ja) 2008-10-21 2012-03-15 メルク・シャープ・エンド・ドーム・コーポレイション ２，５−二置換ピペリジンオレキシン受容体アンタゴニスト
CA2739915A1 (en) * 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
CA2745420A1 (en) 2008-12-02 2010-06-10 Glaxo Group Limited N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0] hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof
KR20110091582A (ko) 2008-12-02 2011-08-11 글락소 그룹 리미티드 Ｎ-｛［1ｒ,4ｓ,6ｒ-3-(2-피리디닐카르보닐)-3-아자비시클로［4.1.0］헵트-4-일］메틸｝-2-헤테로아릴아민 유도체 및 그의 용도
EP2491034B1 (en) 2009-10-23 2013-12-18 Janssen Pharmaceutica, N.V. Fused heterocyclic compounds as orexin receptor modulators
JP5848251B2 (ja) 2009-10-23 2016-01-27 ヤンセン ファーマシューティカ エヌ．ベー． オレキシン受容体調節因子としての縮合複素環式化合物
JP5759470B2 (ja) 2009-10-23 2015-08-05 ヤンセン ファーマシューティカ エヌ．ベー． オレキシン受容体調節因子としての二置換オクタヒドロピロロ［３，４−ｃ］ピロール

Also Published As

Publication number Publication date
EA024106B1 (ru) 2016-08-31
IL232462A0 (en) 2014-06-30
NZ625896A (en) 2016-04-29
EA201400553A1 (ru) 2014-10-30
CN103917538A (zh) 2014-07-09
JP2014532753A (ja) 2014-12-08
IN2014CN04127A (pt) 2015-07-10
SI2776430T1 (sl) 2016-06-30
EP2776430B1 (en) 2016-03-16
DK2776430T3 (en) 2016-05-09
HRP20160678T1 (hr) 2016-07-15
CN103917538B (zh) 2016-08-24
MY167791A (en) 2018-09-26
KR20140096338A (ko) 2014-08-05
CL2014000659A1 (es) 2014-08-18
TW201632517A (zh) 2016-09-16
BR112014010617A8 (pt) 2017-12-26
BR112014010617B1 (pt) 2021-12-14
TWI565703B (zh) 2017-01-11
ZA201404189B (en) 2017-08-30
CA2846568A1 (en) 2013-05-16
TWI555747B (zh) 2016-11-01
AU2012335194B2 (en) 2017-05-25
CY1117638T1 (el) 2017-04-26
ES2572703T3 (es) 2016-06-01
PL2776430T3 (pl) 2016-09-30
MX343837B (es) 2016-11-24
SG11201401665WA (en) 2014-09-26
JP5718535B2 (ja) 2015-05-13
AR088692A1 (es) 2014-06-25
MX2014005635A (es) 2014-06-23
KR101676930B1 (ko) 2016-11-16
EP2776430A1 (en) 2014-09-17
US9150566B2 (en) 2015-10-06
AU2012335194A1 (en) 2014-07-03
HUE029239T2 (en) 2017-02-28
TW201323421A (zh) 2013-06-16
CA2846568C (en) 2020-01-14
UA112317C2 (uk) 2016-08-25
HK1199022A1 (zh) 2015-06-19
IL232462A (en) 2016-11-30
WO2013068935A1 (en) 2013-05-16
US20150158855A1 (en) 2015-06-11

Similar Documents

Publication Publication Date Title
BR112014010617A2 (pt) derivados de 2-(1,2,3-triazol-2-il)benzamida e 3-(1,2,3-triazol-2-il)picolinamida como antagonistas do receptor de orexina
BR112014030173A2 (pt) derivados de benzimidazol-prolina
BR112019001551A2 (pt) moduladores do receptor de piperidina cxcr7
BR112015007516A2 (pt) antagonistas do receptor de orexina que são derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)- pirrolidin-1-il]-metanona
BR112015013463A2 (pt) derivados de carboxamida indol como antagonistas do receptor de p2x7
BR112012031561A2 (pt) morfolino pirimidinas e seu uso em terapia.
CR20140182A (es) Nuevos derivados de ciclohexilamina que tienen actividad como agonistas adrenérgicos b2 y como antagonistas muscarínicos m3
BR112014017735A8 (pt) Compostos derivados de amida heterocíclicos como antagonistas do receptor de p2x7, composição farmacêutica, e, uso de um composto
BR112014031755A8 (pt) Derivados de 1-[m-carboxamido (hetero) aril-metil]-heterociclil-carboxamida
BR112015023161A2 (pt) derivados de piridin-4-ila
BR112012029272A2 (pt) bis-(difluorometil)-pirazol como fungicida.
BR112017015093A2 (pt) derivados de hidroxialquil-piperazina como moduladores do receptor cxcr3
BR112015030095A2 (pt) moduladores do receptor de cxcr7
BR112017015116A2 (pt) derivados de (r)-2-metil-piperazina como moduladores do receptor cxcr3
BR112016001238A8 (pt) Derivados de 1-(piperazin-1-il)-2-([1,2,4]triazol-1-il)-etanona, seus usos e composição farmacêutica os compreendendo
BR112013017570A2 (pt) compostos de pirazola como antagonistas de crth2
BR112015023560A8 (pt) Novos derivados de acrilamida como agentes antimaláricos
UA112586C2 (uk) Похідні бензімідазолпроліну
BR112014016896A2 (pt) derivados de heteroarilamida tendo propriedades antiandrogênicas

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: IDORSIA PHARMACEUTICALS LTD (CH)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: ACTELION PHARMACEUTICALS LTD (CH)

B25C Requirement related to requested transfer of rights

Owner name: ACTELION PHARMACEUTICALS LTD (CH)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: IDORSIA PHARMACEUTICALS LTD (CH)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/11/2012, OBSERVADAS AS CONDICOES LEGAIS.